Q-omics provides the consensus-scored TMEM39B profile across patient tissues and cancer cell-line models. TMEM39B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM39B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM39B RNA expression shows 18,578 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TMEM39B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM39B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM39B survival associations across molecular data types. TMEM39B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM39B RNA expression–survival associations across cancer types. High TMEM39B expression shows unfavorable associations in ACC, MESO, LIHC, LGG and UVM, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM39B RNA expression.
This table summarizes TMEM39B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM39B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM39B shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, COAD and LUSC. The HNSC box plot shows higher TMEM39B RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with TMEM39B in patient tissues and cancer cell lines. In patient samples, TMEM39B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM39B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
